Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 449-455

  Ruane, Peter J ^a   Dejesus, Edwin ^b   Berger, Daniel ^c   Markowitz, Martin ^d   Bredeek, U Fritz ^e   Callebaut, Christian ^f   Zhong, Lijie ^f   Ramanathan, Srini ^f   S Rhee, Martin ^f   Fordyce, Marshall W ^f   Yale, Kitty ^f  

^a Peter J Ruane MD Inc   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c AIDS Research Alliance   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e Metropolis Medical   (United States)

^f Clinical Research   (United States)

Author keywords

Antiretroviral therapy; Dose response; Pharmacodynamics; Pharmacokinetics; Reverse transcriptase inhibitors

Indexed keywords

PLACEBO; PRODRUG; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL;

ADULT; AGED; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THORAX PAIN; TREATMENT DURATION; VIRUS LOAD;

ADENINE; ADULT; ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NAUSEA; ORGANOPHOSPHATES; ORGANOPHOSPHONATES; RNA, VIRAL; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; VIRAL LOAD; YOUNG ADULT;

EID: 84880229518     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182965d45     Document Type: Conference Paper

References (17)

1. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients:facts and hypotheses. Clin Infect Dis. 2011;53:1127-1129.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Vol.
3. Rev ed. Atlanta:U.S. Department of Health and Human Services, CDC; 2007:1-54. Accessed March 27, 2013.
4. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502.
5. Stone VE, Jordan J, Tolson J, et al. Potential impact of once daily regimens on adherence to HAART [abstract]. Paper presented at:40th Annual Meeting of the Infectious Disease Society of America; October 24-27, 2002; Chicago, IL. p. 129. Abstract 486.
6. Chesney M.A. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 2):S171-176.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at:http://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section I-30, Accessed March 27, 2013.
8. VIREAD-(Tenofovir Disoproxil Fumarate) Tablets and Powder. US Prescribing Information. Foster City, CA:Gilead Sciences Inc; 2012.
9. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)- 1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy] propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008;74:92-100.
10. Markowitz M, Zolopa A, Ruane P, et al. GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. Paper presented at:18th Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA.
11. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898-1906.
12. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.
13. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1:results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201:814-822.
14. Liegler T, Abdel-Moshen M, Atchison R, et al. Sensitive quantitation of drug resistant minor variants using a simplified design that tolerates viral sequence heterogeneity. In:17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 563.
15. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 2003;17:1151-1156.
16. Cassetti I, Etzel A, Madruga J, et al. The 10-year safety and efficacy of tenofovir DF (TDF)-containing HAART in antiretroviral naïve patients [Poster Presentation]. J Int AIDS Soc. 2010;13:86-87.
17. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy:summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160.